Ренитек

Quick links to important sections

Ренитек

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ренитек

Quick Facts

Property Description
Active ingredient Enalapril maleate
Form Tablet
Pharmacological class Angiotensin Converting Enzyme (ACE) inhibitor
General purpose Reduce systemic blood pressure and vascular resistance
Origin Synthetic Prodrug

What Type of Medicine is Ренитек?

Ренитек (Renitec) is a prescription-only pharmaceutical agent containing the active ingredient Enalapril maleate, classified as an Angiotensin Converting Enzyme (ACE) inhibitor. The medicine is supplied as a single-ingredient solid tablet designed for oral administration. As a well-established ACE inhibitor, its therapeutic application is clinically recognized for chronic management of conditions requiring cardiovascular stabilization. This classification confirms its role as a key modulator of blood pressure and fluid balance by influencing the body's hormonal systems.

Is Enalapril Maleate a Prodrug?

Yes, Enalapril is specifically designated as a synthetic prodrug. This means the chemical substance is administered in an inactive form, and it must be converted by the body—through a metabolic process called hydrolysis—into its true active metabolite, Enalaprilat, to exert its effects. This chemical structure supports its function as a long-acting preparation. Furthermore, its primary action is mediated by the active metabolite Enalaprilat.

What is the General Purpose of Ренитек?

The general therapeutic purpose of this type of medicine is to reduce the stress and resistance within the cardiovascular system, a common need in individuals with persistent high blood pressure. By inhibiting the ACE enzyme, Ренитек prevents the formation of the potent vasoconstrictor, Angiotensin II, allowing blood vessels to relax or dilate. This fundamental action translates directly into the general benefit of easing the force required for the heart to circulate blood, thereby reducing elevated pressure on the cardiovascular system.

What side effects are possible with Ренитек?

Possible Side Effects and Safety Information

The safety profile for Enalapril maleate (Ренитек) is officially documented by regulatory authorities, classifying potential adverse reactions by both frequency and the body system affected. These classifications establish the expected risk profile of the medicine, strictly detailing what patients may experience.


Frequency-Classified Adverse Reactions

Adverse events are formally grouped according to their documented occurrence rates:

  • Very Common: Documented effects include dizziness, headache, and a persistent, non-productive cough, which is a recognized characteristic of the ACE inhibitor class.
  • Common: Reactions such as fatigue, asthenia (lack of energy), nausea, diarrhea, and hypotension (low blood pressure) are frequently listed.
  • Uncommon/Rare: Less frequent documented reactions include angioedema (swelling of the face, limbs, lips, tongue, or throat), taste disturbance, palpitations, and rare but serious reactions such as hepatic failure and agranulocytosis.

Serious Adverse Reactions and Safety Constraints

Official labeling specifically highlights risks that require particular attention. Angioedema is a serious adverse reaction documented to potentially involve the larynx or glottis. Acute renal failure and severe blood disorders are also included in the serious reaction listings.

Safety is not universally consistent across all patient groups. The medicine is formally contraindicated in pregnancy due to documented risks of fetal morbidity. The labeling also notes that ACE inhibitors may be associated with a higher rate of angioedema in Black patients. Furthermore, hypotension is explicitly noted as being more likely to occur after the initial dose or upon a dose increase, establishing a time-related safety pattern documented in official texts.

Overdose and Emergency Response

Overdose and when to seek help: Renitec (Enalapril)

The official regulatory information for Renitec (Enalapril) overdose is focused on the immediate, potentially severe consequences of excessive blood pressure lowering and required emergency actions.

Documented Overdose Manifestations

Overdose presentations are primarily an extension of the therapeutic effects, including profound hypotension (extremely low blood pressure), dizziness, tachycardia (rapid heart rate), or bradycardia (slow heart rate). More serious manifestations documented include stupor and hypotension-related complications such as acute renal failure and, in rare instances, cardiac arrest.

Emergency Response and Actions

Immediate medical help must be sought (e.g., call emergency services or a Poison Control Center) upon any suspicion of overdose, regardless of whether symptoms are currently present.

Treatment is supportive, as no specific chemical antidote exists. Regulatory guidance includes placing the patient in a supine position and immediately initiating volume expansion with an intravenous normal saline infusion to correct hypotension. For massive, recent ingestion, procedural actions like the use of activated charcoal or gastric lavage may be considered. Continuous monitoring of blood pressure, serum electrolytes, and renal function is mandatory during the observation period. The active metabolite, enalaprilat, is known to be dialyzable, making hemodialysis an option for severe or refractory cases.

Therapeutic Uses of Ренитек

What Ренитек Treats: Main Uses and Benefits

The primary therapeutic role of this medication is the long-term management of cardiovascular conditions, generally focusing on reducing systemic pressure and easing the heart's workload, and contributes to maintaining functional stability.

This therapy is commonly used for managing conditions such as persistent high blood pressure (hypertension), symptomatic congestive heart failure (CHF), and asymptomatic left ventricular dysfunction.

This therapy is relevant in clinical settings where supportive symptomatic management is appropriate. It helps to ease symptoms related to physical discomfort, such as shortness of breath and fatigue, which often interfere with daily functioning in patients with heart failure. Furthermore, its application may assist in managing conditions associated with heightened symptoms, which contributes to long-term well-being.

“This application is relevant for managing an underlying condition to assist with maintaining functional stability.”

This medication is also commonly used in patient groups with specific risk factors, such as those with coexisting diabetes. Its use is relevant for easing the stress linked to organ-specific functional stress, and may assist in the maintenance of renal function by helping to reduce proteinuria.


Quick Fact: Support for Systemic Imbalance The therapy may assist in easing the overall systemic burden, which supports general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ренитек? — Official Regulatory Information

The eligibility profile for Ренитек (Enalapril maleate) is strictly defined by governmental regulatory authorities and outlines which populations are permitted to use the medicine and which are prohibited or restricted.

Absolute Contraindications (Must Not Use)

Category Restriction
Hypersensitivity/Angioedema Patients with known hypersensitivity to any ACE inhibitor or a history of drug-related or hereditary angioedema.
Pregnancy Use during the second and third trimesters of pregnancy.
Drug Combinations Concomitant use with sacubitril/valsartan or with aliskiren-containing products in patients with diabetes or severe renal impairment.

Age and Condition Restrictions

Use is not recommended for neonates (children under one month of age). The medicine is approved for hypertension in children older than one month, but not recommended for those with severely reduced Glomerular Filtration Rate (GFR). Use requires caution in older adults and in patients with impaired renal function or severe volume depletion (e.g., due to dialysis or vomiting). Discontinuation is advised immediately upon detection of pregnancy, and official labeling advises against breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Enalapril maleate is defined by officially documented patterns that impose specific restrictions on co-administration with other substances.

Formal Regulatory Restrictions

Restriction Type Interacting Substance Official Constraint
Contraindicated Sacubitril/Valsartan Must not be administered within 36 hours of switching to or from Enalapril therapy.
Contraindicated Aliskiren Prohibited in patients with diabetes mellitus or renal impairment (GFR < 60 mL/min/1.73 m²).

Pharmacodynamic and Clearance Interactions

Co-administration with agents affecting the body’s potassium balance may increase the risk of hyperkalemia (elevated serum potassium levels). This includes Potassium-Sparing Diuretics (e.g., Spironolactone) and Potassium Supplements or salt substitutes containing potassium.

The combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may result in a risk of deterioration of renal function.

Enalapril formally reduces the clearance of Lithium, leading to increased serum Lithium concentrations and the risk of toxicity. Additive effects on blood pressure are noted when combined with Alcohol or other antihypertensive agents. Furthermore, the co-administration with mTOR inhibitors or injectable Gold carries a documented increased risk of angioedema or nitritoid reactions, respectively.

Mechanism of Action

The pharmacological action of Ренитек is mediated by its active metabolite, enalaprilat, a competitive inhibitor of the angiotensin-converting enzyme (ACE). ACE is a metalloprotease that converts the inactive decapeptide angiotensin I into the active octapeptide angiotensin II.

By inhibiting ACE, enalaprilat reduces the systemic formation and plasma concentration of angiotensin II. Angiotensin II functions as a potent vasoconstrictor and stimulates the adrenal cortex to secrete aldosterone. Consequently, the downstream cascade of ACE inhibition involves a decrease in total peripheral resistance due to diminished vasoconstriction. Additionally, the suppression of aldosterone secretion modulates renal processes, influencing the reabsorption of sodium and water.

The ACE enzyme is also identical to kininase II, which degrades the vasodilator peptide bradykinin. Inhibition of this enzyme leads to increased local levels of bradykinin. This rise in bradykinin contributes to vascular dilation. The collective systemic physiological consequence is the modulation of vascular tone and fluid homeostasis, primarily through the suppression of the renin-angiotensin-aldosterone system (RAAS).

Dosage and Administration Information

The use of Ренитек (Enalapril maleate) follows specific clinical parameters defining the routes, dosages, and timing for its administration. The medicine is primarily taken via the oral route as a tablet in strengths ranging from 2.5 mg to 20 mg, though an injectable form of its active metabolite, Enalaprilat, is available for specialized settings. The tablets may be taken with or without food, as the presence of a meal does not significantly alter its absorption.

Common administration protocols involve a low initial dose followed by a regimen of gradual titration. For most adult indications, initial dosing starts at 5 mg once daily for hypertension or 2.5 mg once or twice daily for heart failure, with the dose slowly increased over two to four weeks toward a maintenance range. The daily dose may be administered either once daily or divided into two doses, reaching a maximum of 40 mg per day for adults.

Clinical guidelines specify adjustments for specific populations. For patients with renal impairment, the starting dose is lowered to 2.5 mg daily if the creatinine clearance is 30 mL/min or less. Furthermore, patients undergoing hemodialysis are instructed to take their dose after the procedure. If a dose is missed, it should be omitted if close to the next scheduled time, and the dose should not be doubled to compensate. The preparation of the oral solution also requires reconstitution from a powder.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ренитек (Enalapril)

This summary is designed to help you understand the types of studies that have been conducted on Ренитек (Enalapril), the outcomes researchers have examined, and what aspects of the treatment are still being explored. This information describes group patterns observed in research, not personal outcomes or medical advice.


Evidence for Use in High Blood Pressure (Hypertension)

Research exploring how symptoms change over time has involved numerous studies, including short-term and longer-duration Randomized Controlled Trials (RCTs). These studies primarily monitored changes in seated systolic and diastolic blood pressure readings. They also research examined whether studies tracked the percentage of patients meeting pre-defined blood pressure thresholds and studies monitored the occurrence of major cardiovascular outcomes, such as strokes. Findings describe patterns observed in the studies, including measured changes in both systolic and diastolic blood pressure within the groups studied. Data for certain groups, such as very young children (under 1 month of age), remain insufficient.

Evidence for Use in Symptomatic Heart Failure

The evidence for Ренитек in conditions marked by functional limitations like symptomatic heart failure is based on large, multi-year, placebo-controlled trials. Studies explored how the use of Ренитек, alongside standard care, evaluated measures of all-cause mortality and outcomes reflecting daily functioning or activity level, such as the frequency of hospital admissions due to heart failure. Research highlights changes measured during the study period, with the patient groups receiving Ренитек showing patterns in mortality and hospitalization rates that were monitored, alongside separate monitoring of patients receiving a placebo. The evidence was mainly generated in studies involving patients with a reduced ejection fraction (HFrEF).


What is Still Uncertain About Ренитек Studies

A key limitation is that long-term effects are not fully established across all indications, especially for outcomes in children and adolescents with hypertension. Follow-up durations were limited in many of the initial trials compared to the lifelong nature of chronic conditions, leading to uncertainty about the most durable patterns. Evidence is limited for individuals with heart failure where the left ventricular function is preserved (HFpEF), as most major studies focused on those with reduced function. The comparative evidence is lacking in some areas, meaning that head-to-head trials against all other contemporary therapies are not always available.

Frequently Asked Questions (FAQ)

Common questions about Ренитек (FAQ)


Q: Is Ренитек used for high blood pressure only?

A: According to official product information, Ренитек (Enalapril maleate) is used for more than just high blood pressure (hypertension). It is also indicated for the treatment of symptomatic heart failure and for the management of asymptomatic left ventricular dysfunction in adult patients. These uses are outlined in regulatory documents.


Q: Is Ренитек commonly prescribed for heart failure?

A: Yes, official documentation indicates that Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure. It is typically used in combination with other standard medicines as part of a comprehensive management plan. The medicine's use for this condition is supported by large-scale clinical evidence.


Q: Is the cough side effect from Ренитек usually temporary?

A: A persistent, dry cough is a recognized and common side effect of the ACE inhibitor class of medicines. Official information notes that this cough may go away once the medication is stopped (discontinued). If a patient experiences a persistent cough, discussing this with a healthcare provider is generally recommended.


Q: What happens if you stop taking Ренитек suddenly?

A: Official regulatory text suggests that abrupt discontinuation of this medicine has not been associated with a rapid or uncontrolled increase in blood pressure (a condition known as rebound hypertension). Decisions regarding stopping treatment are typically made in consultation with a qualified healthcare professional.


Q: Why is regular blood testing often suggested when using Ренитек?

A: Regulatory guidance recommends routine monitoring because of the way the medicine works in the body. Specifically, it is suggested to check renal function (kidney health) and serum potassium levels when starting treatment and during dosage adjustments. This is done to prevent or detect certain changes, such as high blood potassium.


Q: Can Ренитек affect exercise performance?

A: Official safety listings indicate that common side effects can include general fatigue and asthenia (a lack of energy). These documented effects may, in turn, impact a person’s perceived capacity or energy level for physical activities or exercise.


Q: Can high salt intake reduce the effects of Ренитек?

A: High blood pressure is linked to high-sodium foods, which can worsen the condition. In general, high salt intake may reduce the effectiveness of blood pressure-lowering medicines. The management of high blood pressure often involves advice to maintain a low-sodium diet, as noted in general health guidelines.


Q: Is Ренитек the same type of drug as a beta-blocker?

A: No, official classification places Ренитек in the class of Angiotensin-Converting Enzyme (ACE) inhibitors. This is a different class of medicine from beta-blockers, as they work through distinct biological mechanisms to achieve their therapeutic effects on the cardiovascular system.


Q: Can Ренитек be taken by people with kidney problems?

A: The medicine can be used by patients with reduced kidney function, but it requires formal dose adjustments and careful monitoring. Official guidelines state that the starting dose must be formally lowered for patients with significant renal impairment to ensure safety. Regular monitoring of kidney function is advised.


Q: Are there any common over-the-counter pain relievers that can interact with Ренитек?

A: Official regulatory labeling specifically highlights a potential interaction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common over-the-counter pain relievers. Combining these medicines may carry a risk of deterioration of renal function (worsening kidney health).


Q: Can Ренитек be used in patients with a history of liver issues?

A: Official information notes that Ренитек is associated with rare instances of acute liver injury, listing hepatic failure as a serious adverse reaction. However, regulatory documents do not formally recommend a dosage adjustment based on pre-existing hepatic impairment alone.


Q: Does Ренитек affect blood sugar levels?

A: Regulatory-associated information indicates that enalapril can lower blood sugar levels. Patients with diabetes may be advised to monitor their blood sugar more frequently when initiating treatment or adjusting their dose. This is an important consideration for diabetes management.


Q: Can older adults (70+) generally use Ренитек?

A: Use in older patients (generally defined as over 65 years) is permitted according to official guidance. However, the dose should be specifically determined in line with the patient's renal function (kidney performance). This reflects a need for individual medical assessment.


Q: Are there any specific foods or drinks that should be avoided with Ренитек?

A: Official warnings advise caution regarding substances that affect the body's potassium balance. Patients should specifically avoid using salt substitutes containing potassium and should use caution with other foods high in potassium due to the risk of hyperkalemia (high blood potassium levels).


Q: Does Ренитек cause weight gain?

A: Weight gain is not listed as a common, uncommon, or rare side effect in official documents. However, the safety profile does note swelling of the ankles and feet (edema) as a potential side effect, which relates to fluid collection.


Q: Can I take non-prescription cold medicine while using Ренитек?

A: Caution is advised because some non-prescription cold medicines contain ingredients like ephedrine or noradrenaline, which are documented to interact with ACE inhibitors. If a patient is considering using non-prescription cold medicine, reviewing this with a healthcare provider is important due to potential interactions.


Q: Does Ренитек need to be taken at a specific time of day?

A: The maintenance dose for Ренитек can generally be taken at any time of day. However, the first dose may sometimes be advised to be taken before bedtime to help manage potential dizziness. It is generally advised that the time of day chosen for administration is kept consistent.


Q: Is there a generic version of Ренитек available?

A: Yes, Ренитек is a brand name. The medicine's active ingredient, enalapril maleate, is widely available as a generic medicine. Generic versions contain the same active ingredient and are approved by regulatory authorities.


Q: Do weather or temperature extremes affect how Ренитек works?

A: Official warnings advise patients to be careful to drink enough water during exercise and in hot weather, especially if sweating heavily, while using this medication. This measure helps prevent symptoms of low blood pressure (hypotension) related to volume depletion.


Q: Can Ренитек cause problems with taste?

A: Taste disturbance (or a loss of taste sensation) is listed as an uncommon or rare side effect documented in official safety information. If a taste disturbance occurs, discussing this change with a healthcare provider is generally advised.


Q: Are there any reports of Ренитек causing skin rashes?

A: Official safety warnings do list a skin rash as a potential side effect, although this is classified as an uncommon reaction (meaning it occurs less frequently than a common reaction). Severe forms of rash are listed alongside other serious adverse events.


Q: Is the effect of Ренитек permanent after I stop taking it?

A: No, the effects of the drug cease after discontinuation. The medicine works by temporarily inhibiting an enzyme in the body, and the body gradually eliminates the active substance. The effects are not considered permanent after treatment is stopped.


Q: Does Ренитек interact with antidepressants?

A: The medicine may have additive effects in lowering blood pressure when combined with some types of antidepressants (e.g., tricyclic antidepressants). This combination could potentially increase the risk of side effects such as feeling dizzy or lightheaded when standing up.


Q: How does the official evidence describe the research done on Ренитек for heart protection?

A: Official documentation notes that studies have monitored the drug’s potential to modulate major cardiovascular outcomes in patient groups, including monitoring for effects on heart attack (myocardial infarction) and stroke. The drug is considered beneficial for many patients at risk for heart disease beyond just treating hypertension.


Q: What is the usual duration of a course of treatment with Ренитек?

A: Treatment for chronic conditions like hypertension or heart failure is typically considered long-term. This class of medication is generally prescribed for the duration of the chronic condition.


Q: Is it common to take Ренитек once or twice a day?

A: For the treatment of hypertension, the official maintenance dose is generally taken once per day. However, dosing may also be divided into two doses (e.g., every 12 hours) depending on the patient's specific needs, making both regimens possible.


Q: How quickly does Ренитек typically begin to have an effect?

A: Official regulatory documents indicate that the onset of its blood pressure-lowering activity is typically observed within about one hour after taking a single oral dose. The peak reduction in blood pressure is usually reached within four to six hours after administration.

How should Ренитек be stored and disposed of?

How to Store and Dispose of Renitec (Enalapril Maleate)

Renitec tablets must be stored at Controlled Room Temperature, generally defined as between 15 C and 30 C, or specifically below 25 C depending on regional guidance. The medication must be kept in a cool, dry place and be actively protected from moisture and excessive heat, which can cause the tablets to degrade.

Packaging and Safety

Tablets must remain in the original blister pack until the time of use, and the container should be kept tightly closed. All medicine must be stored out of the sight and reach of children.

Disposal

Unused or expired tablets should be managed by asking a pharmacist what to do with the leftover medicine, or by following local, regional, or national regulations. The product must not be disposed of into sewers or other water sources.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ренитек found in:

A-Z Index: